Andrew D. Zelenetz

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

96h-index42.4kcitations757works4.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(563), Chronic Lymphocytic Leukemia Research(307), Viral-associated cancers and disorders(128), Lung Cancer Treatments and Mutations(98), CNS Lymphoma Diagnosis and Treatment(95)

Publications752 total

Kidney Involvement in Sarcoidosis-Lymphoma Syndrome: A Report of Two Cases
CEN Case Reports·2026Open Access
Intratumoral Microbiome Signatures Detection Impacts on DLBCL Outcomes Pre-CART
Transplantation and Cellular Therapy·2026
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study
Blood Advances·2026Open Access
Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma—A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial
Cancers·2026Open Access
Romiplostim for Prevention of Severe Chemotherapy-Induced Thrombocytopenia in Lymphoma Patients—Phase I Study
Cancers·2026Open Access
CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis
Blood·2025· 2 cited
Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop
Blood Advances·2025Open Access
Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma
Haematologica·2025Open Access
Does increased PET avidity predict follicular lymphoma transformation? evidence from a large observational study
Blood·2025
Pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter, Phase 2 trial
Blood·2025Open Access
Updated results from a Phase II study of minimal residual disease-guided venetoclax + obinutuzumab for the initial treatment of fit patients with chronic lymphocytic leukemia
Blood·2025
Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study
Blood·2025
Post-treatment outcomes of TP53-mutant Mantle Cell Lymphoma patients treated with frontline zanubrutinib, obinutuzumab, and venetoclax (BOVen): Durable responses in patients who achieve complete remissions with undetectable MRD
Blood·2025
Insights in the management of older adults with mantle cell lymphoma amidst a changing therapeutic landscape: Lessons from a 25-year institutional experience
Blood·2025
Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need
Blood·2025Open Access
Transformed Waldenström macroglobulinemia is associated with poor outcomes and chemorefractory disease
Blood·2025Open Access
Epcoritamab with lenalidomide and tafasitamab in patients with relapsed/refractory diffuse large B cell lymphoma (ECLAT), a phase 2 investigator-initiated trial
Blood·2025Open Access
Are all GELF criteria created equal? utility of individual GELF criteria as guidance for treatment initiation in patients with advanced stage FL
Blood·2025· 1 citedOpen Access
EZH2 and CREBBP mutation status identify a subset of patients who benefit from bendamustine- over CHOP/CVP-based immunochemotherapies in follicular lymphoma: Findings from the GALLIUM trial and validation in a large international cohort
Blood·2025
Advanced practice provider led programs improve patient access: The APP lymphoma diagnostic program
Blood·2025Open Access
page 1 of 38Next →

Frequent Co-authors

Craig H. Moskowitz(17), Steven M. Horwitz(12), Julie M. Vose(12), Carol S. Portlock(12), Joachim Yahalom(12), David J. Straus(11), Ariela Noy(11), Mark Kaminski(9), Paul A. Hamlin(9), Ranjana H. Advani(8), Jonathan W. Friedberg(7), Ann S. LaCasce(7), Leo I. Gordon(7), Jeremy S. Abramson(7), Stephen D. Nimer(7), John P. Leonard(6), Martha Glenn(6), Heiko Schöder(6), Matthew J. Matasar(6), Alison J. Moskowitz(6)